CommercialCoverageLow impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Hematology, Oncology, Allergy & Immunology·Medical Policy
Effective date
Jan 21, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated coverage criteria for two specialized treatments: Betibeglogene autotemcel (Zynteglo) for beta-thalassemia and C1 Esterase Inhibitor treatments for hereditary angioedema with normal C1 inhibitor levels. Both policies include detailed diagnostic and clinical requirements that must be documented for coverage approval.
Action Required
Before January 21, 2026: Review updated coverage criteria for Betibeglogene autotemcel (Zynteglo) and C1 Esterase Inhibitor treatments. Ensure prior authorization requests include all required documentation including genetic testing results, transfusion history, performance status assessments, and organ function testing as specified in the new criteria. Update prior authorization checklists to reflect the detailed requirements for each treatment.